ClinicalTrials.gg
TerminatedNCT02393378TELLUSUpdated Feb 5, 2019Results posted

Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate

A Phase 2 interventional study of Namilumab and Adalimumab in Rheumatoid Arthritis, sponsored by Takeda. Terminated at 13 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-05.

Sponsored by Takeda · Phase 2, Interventional, and Treatment

Why this study was terminated
Strategic decision - to understand data from psoriasis study - NCT02129777 and wait for results of formal proof of concept study - NCT02379091.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
7
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.

Enrollment
87th of 87
7 · median 160
Started
2015
with 7 others
Phase 2
9 of 87
2 open now
Registered
66th of 87
by date

Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 87th largest by enrollment, is one of 8 that started in 2015, is one of 9 in phase 2, and was the 66th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies testing adalimumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of namilumab in combination with existing methotrexate (MTX) therapy over 24 weeks in participants with moderate to severe early rheumatoid arthritis (RA), diagnosed within 6 months and inadequately controlled by MTX alone.

Read the detailed description

The drug being investigated in this study is namilumab for the treatment of moderate to severe Rheumatoid Arthritis (RA). This study will evaluate the efficacy and safety of namilumab in participants diagnosed with RA within 6 months and insufficiently controlled by methotrexate (MTX) alone.

The study will enroll approximately 36 patients, who will be randomly assigned in a 2:1 ratio to the following open label treatment groups:

  • Namilumab 150 mg + MTX + folic acid
  • Adalimumab 40 mg + MTX + folic acid

Imaging techniques, including Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI), will be used to measure changes in the dominant hand and the wrist.

This multi-center trial will be conducted worldwide. The overall time to participate in this study is a maximum of 42 weeks, including follow-up period. Participants will make 16 visits to the site and will be followed up by telephone twice after end of treatment.

A strategic decision was made to stop the study on 18 December 2015 in order to fully understand the data from the psoriasis study (ClinicalTrials.gov Identifier:NCT02129777) and wait for the results of the formal proof of concept study (ClinicalTrials.gov Identifier: (NCT02379091) in participants with rheumatoid arthritis.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is diagnosed with adult onset rheumatoid arthritis (RA) as defined by the 2010 The American College of Rheumatology (ACR)/The European League Against Rheumatism criteria for the classification of RA within 6 months prior to Screening Visit.
  • Has active disease defined as:

    1. swollen joint count ≥4 and tender joint count ≥4 (referred to the 28 joint-count system) at Screening and Baseline Visits, and
    2. C-reactive protein ≥4.3 mg/L and erythrocyte sedimentation rate ≥28 mm/hr at Baseline Visits, and
    3. imaging (ultrasound power doppler) evidence of moderate to severe inflammation of at least 1 joint of the dominant hand metacarpophalangeal (MCP) and/or wrist) at Screening and Baseline Visits.
  • Is receiving current treatment with Methotrexate (MTX) for RA.
  • Received MTX for at least 3 months prior to the Screening Visit.
  • Received treatment with MTX ≥15 to 25 mg/week at a stable dose via the same route of administration and formulation for at least 8 weeks prior to the Baseline Visit, OR
  • Participants on a stable dose for at least 8 weeks of MTX of ≥7.5 mg/week, if the MTX dose has been reduced for reasons of documented intolerance to MTX.
  • Is willing to continue or initiate treatment with oral folic acid (at least 5 mg/week) or equivalent and be treated during the entire trial (mandatory co-medication for MTX treatment).
  • Has a posterior, anterior, and lateral chest x-ray obtained within the last 3 months before Screening or at the Screening visit without any signs of pulmonary disease.

Exclusion criteria

Exclusion Criteria:

  • Has received biologic disease-modifying antirheumatic drugs for the treatment of RA.
  • Have a history of or currently inflammatory joint disease other than RA (e.g., gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, or Lyme disease) or other systemic disorder (eg, systemic lupus erythematosus, inflammatory bowel disease, scleroderma, inflammatory myopathy, mixed connective tissue disease, or other overlap syndrome).
  • Has any major systemic features of RA, for example, Felty's syndrome, vasculitis, or interstitial fibrosis of the lungs.
  • Diagnosed with primary fibromyalgia that would make it difficult to appropriately assess RA activity for the purposes of this study or a diagnosis of any systemic inflammatory condition other than RA.
  • Has a history of juvenile idiopathic arthritis or RA onset prior to age 16 years.
  • Required to take excluded medications
  • Not willing to take folic/folinic acid (as part of MTX regimen, according to country-specific practices) in order to minimize toxicity.
  • Has an underlying condition that predisposes to infections (e.g., immunodeficiency, poorly controlled diabetes history, splenectomy).
  • Has a history of interstitial lung disease, for example, history of chronic or recurrent pulmonary infection where macrophages are important for the clearance of the infection, for example, pneumocystis carinii pneumonia, allergic bronchopulmonary aspergillosis, nocardia infections, Actinomyces infection.
  • Presence or history of active tuberculosis (TB) or latent TB infection, where no anti-TB treatment has been given or where successful completion of an appropriate course of anti-TB therapy cannot be documented.
  • A positive QuantiFERON-TB Gold test and/or evidence of active or latent TB by chest x-ray at Screening Visit, not accompanied by initiation of an approved regimen of anti-TB therapy at least 12 months prior to the Baseline Visit.
  • Has a known history of infection with virus, virus, or (HIV), or has serological findings at the Screening Visit which indicate active or latent hepatitis B, hepatitis C or HIV infection.
  • Has a clinically relevant decrease in lung function at Screening, as defined by an oxygen saturation as measured by pulse oximetry (SpO2) \<94% at rest.
  • Has evidence of clinically significant respiratory disease on the basis of review the data from participants' respiratory assessments including chest x-ray, pulmonary function test ( [FEV1] and forced vital capacity [FVC]) by spirometry performed at Screening). The participants must have SpO2 ≥94%, FEV1 and/or FVC ≥60% of predicted values at Screening or at Baseline and no uncontrolled lung disease. Participant's treatment that has been modified to control lung disease within 24 weeks prior to Screening is exclusionary.
  • Has a history of severe (COPD) and/or history of severe COPD exacerbation(s), or a history of asthma with exacerbations requiring hospitalization, within the last 12 months prior to the Screening Visit.
  • Has an estimated (eGFR) of less than 60 mL/min/1.73m2.History of MTX-associated lung toxicity.
  • Has a history or evidence of a clinically significant disorder (including but not limited to cardiopulmonary, oncologic, renal, metabolic, hematologic or psychiatric), condition or disease that, in the opinion of the investigator and Takeda physician, would pose a risk to participant safety or interfere with the study evaluation, procedures or completion.
  • Has any significant cardiac disease (eg, coronary artery disease with unstable angina, coronary heart failure Class III and IV, familial long syndrome).
  • Has a history of cancer within the last 10 years except for basal cell or squamous cell carcinomas of the skin or in situ carcinoma of the cervix treated and considered cured.
  • Has a severe psychiatric or neurological disorder.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Adalimumab 40 mg

    Adalimumab 40 mg, subcutaneous (SC) injection at Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 22 as an add-on to weekly existing stable MTX and folic acid as per prescribed medication.

    Drug: Adalimumab · Drug: Methotrexate · Drug: Folic Acid

  • Active comparator
    Namilumab 150 mg

    Namilumab 150\*2 mg, SC injection at Week 0 followed by 150 mg, SC injections at Weeks 2, 6, 10, 14, 18, and 22 as an add-on to weekly existing stable MTX and folic acid as per prescribed medication.

    Drug: Namilumab · Drug: Methotrexate · Drug: Folic Acid

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Synovitis, Erosion and Bone Marrow Edema (Osteitis) Score at Week 24

    A Magnetic Resonance Imaging (MRI) of Metacarpophalangeal (MCP) and Wrist of the dominant hand was performed at the baseline and at week 24. Change from the Baseline was assessed according to the Outcome Measures in Rheumatoid Arthritis (RA) Clinical Trials RA-MRI scoring (OMERACT RAMRIS) Standard. RAMRIS score is the sum of its core components: Synovitis Score, Edema Score, and Erosion Score. Synovitis is scored from 0 (normal) to 9 (maximum distension of synovial cavity). Edema is scored 0 (normal) to 69 (maximum articular bone involvement). Erosion is scored from 0 (normal) to 230 (maximum erosion of articular bone). Total RAMRIS score=0 (normal), maximum RAMRIS score=308 (severe structural damage). For Synovial Score, Edema Score, Erosion Score, and RAMRIS score, increasing number = increasing severity.

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Change From Baseline in Dynamic Contrast-enhanced - Magnetic Resonance Imaging (DCE-MRI) Parameters at Week 24

    DCE-MRI was used to measure synovial vascular perfusion. The change from baseline in DCE-MRI parameters of synovial vascular perfusion at Week 24 were measured.

    Time frame: Baseline and Week 24

  2. Number of Participants Who Achieved Remission at Week 24

    Remission is defined as the number of participants who achieved Disease Activity Score 28 based on C-reactive protein (DAS28-CRP) score \<2.6. The DAS28-CRP is a composite measure of inflammation in rheumatoid arthritis (RA) and incorporates a tender and swollen joint count, CRP and patient global assessment of disease activity expressed in a gaussian distribution of variables ranging from 0 to 10. A DAS28-CRP score of \<3.2 suggests a low level of disease activity, while a score of \>5.1 suggests a high level of disease activity. Using the DAS-CRP as a continuous scale allows investigators (and clinicians) to measure a clinically meaningful endpoint following institution of a therapeutic intervention. In RA, clinical remission would therefore be graded as a DAS28 score of ≤2.6 with disease flare accompanying scores of ≥5.1; well-controlled disease is best characterized as fitting in between these two scores.

    Time frame: Week 24

  3. Number of Participants Who Achieved Low Disease Activity at Week 24

    Disease Activity Score 28 based on C-reactive protein (DAS28-CRP) low disease activity is defined as a score \<3.2. The DAS28-CRP is a composite measure of inflammation in RA and incorporates a tender and swollen joint count, CRP and patient global assessment of disease activity expressed in a gaussian distribution of variables ranging from 0 to 10. A DAS28-CRP score of \<3.2 suggests a low level of disease activity, while a score of \>5.1 suggests a high level of disease activity. Using the DAS-CRP as a continuous scale allows investigators (and clinicians) to measure a clinically meaningful endpoint following institution of a therapeutic intervention. In RA, clinical remission would therefore be graded as a DAS28 score of ≤2.6 with disease flare accompanying scores of ≥5.1; well-controlled disease is best characterized as fitting in between these two scores.

    Time frame: Week 24

  4. Number of Participants Who Achieved ACR 20, 50, and 70 at Week 24

    The American College of Rheumatology (ACR) 20 is composite index of improvement in RA proposed by the ACR. ACR20 refers to a composite improvement of 20% in swollen joint count, tender joint count, and 3 or more of the following 5 measures: Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity, Patient Pain VAS, Patient's self-addressed disability (HAQ), Acute-phase reactant (ESR or CRP) The ACR 50 and ACR 70 are similar tools, used to indicate 50% and 70% improvement, respectively.

    Time frame: Week 24

  5. Change From Baseline in DAS28-CRP Score

    The DAS28-CRP is a composite measure of inflammation in RA and incorporates a tender and swollen joint count, CRP and patient global assessment of disease activity expressed in a gaussian distribution of variables ranging from 0 to 10. A DAS28-CRP score of \<3.2 suggests a low level of disease activity, while a score of \>5.1 suggests a high level of disease activity. Using the DAS-CRP as a continuous scale allows investigators (and clinicians) to measure a clinically meaningful endpoint following institution of a therapeutic intervention. In RA, clinical remission would therefore be graded as a DAS28 score of ≤3.2 with disease flare accompanying scores of ≥5.1; well-controlled disease is best characterized as fitting in between these two scores.

    Time frame: Baseline Up to Week 42

07

Results

Posted Feb 5, 2019

Participant flow

Participants took part in the study at 5 investigative sites in Estonia and Russian Federation from 08 April 2015 to 03 November 2016.

Participant flow — Overall Study
MilestoneAdalimumab 40 mgNamilumab 150 mg
Started34
Completed34
Not completed00

Outcome measures

PrimaryChange From Baseline in Synovitis, Erosion and Bone Marrow Edema (Osteitis) Score at Week 24

A Magnetic Resonance Imaging (MRI) of Metacarpophalangeal (MCP) and Wrist of the dominant hand was performed at the baseline and at week 24. Change from the Baseline was assessed according to the Outcome Measures in Rheumatoid Arthritis (RA) Clinical Trials RA-MRI scoring (OMERACT RAMRIS) Standard. RAMRIS score is the sum of its core components: Synovitis Score, Edema Score, and Erosion Score. Synovitis is scored from 0 (normal) to 9 (maximum distension of synovial cavity). Edema is scored 0 (normal) to 69 (maximum articular bone involvement). Erosion is scored from 0 (normal) to 230 (maximum erosion of articular bone). Total RAMRIS score=0 (normal), maximum RAMRIS score=308 (severe structural damage). For Synovial Score, Edema Score, Erosion Score, and RAMRIS score, increasing number = increasing severity.

Time frame:
Baseline and Week 24
Reported as:
Mean · score on a scale
Change From Baseline in Synovitis, Erosion and Bone Marrow Edema (Osteitis) Score at Week 24
score on a scaleAdalimumab 40 mgNamilumab 150 mg
Erosion Score, Change at Week 240.50 ± 0.8660.00 ± 0.500
Synovitis Score, Change at Week 240.17 ± 0.764-1.50 ± 4.770
Osteitis Score, Change at Week 24-0.33 ± 0.764-2.00 ± 3.536
SecondaryChange From Baseline in Dynamic Contrast-enhanced - Magnetic Resonance Imaging (DCE-MRI) Parameters at Week 24

DCE-MRI was used to measure synovial vascular perfusion. The change from baseline in DCE-MRI parameters of synovial vascular perfusion at Week 24 were measured.

Time frame:
Baseline and Week 24
Reported as:
Mean · mL
Change From Baseline in Dynamic Contrast-enhanced - Magnetic Resonance Imaging (DCE-MRI) Parameters at Week 24
mLAdalimumab 40 mgNamilumab 150 mg
Change From Baseline in Dynamic Contrast-enhanced - Magnetic Resonance Imaging (DCE-MRI) Parameters at Week 240.016 ± 0.0253-0.052 ± 0.0662
SecondaryNumber of Participants Who Achieved Remission at Week 24

Remission is defined as the number of participants who achieved Disease Activity Score 28 based on C-reactive protein (DAS28-CRP) score \<2.6. The DAS28-CRP is a composite measure of inflammation in rheumatoid arthritis (RA) and incorporates a tender and swollen joint count, CRP and patient global assessment of disease activity expressed in a gaussian distribution of variables ranging from 0 to 10. A DAS28-CRP score of \<3.2 suggests a low level of disease activity, while a score of \>5.1 suggests a high level of disease activity. Using the DAS-CRP as a continuous scale allows investigators (and clinicians) to measure a clinically meaningful endpoint following institution of a therapeutic intervention. In RA, clinical remission would therefore be graded as a DAS28 score of ≤2.6 with disease flare accompanying scores of ≥5.1; well-controlled disease is best characterized as fitting in between these two scores.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Remission at Week 24
ParticipantsAdalimumab 40 mgNamilumab 150 mg
Number of Participants Who Achieved Remission at Week 2402
SecondaryNumber of Participants Who Achieved Low Disease Activity at Week 24

Disease Activity Score 28 based on C-reactive protein (DAS28-CRP) low disease activity is defined as a score \<3.2. The DAS28-CRP is a composite measure of inflammation in RA and incorporates a tender and swollen joint count, CRP and patient global assessment of disease activity expressed in a gaussian distribution of variables ranging from 0 to 10. A DAS28-CRP score of \<3.2 suggests a low level of disease activity, while a score of \>5.1 suggests a high level of disease activity. Using the DAS-CRP as a continuous scale allows investigators (and clinicians) to measure a clinically meaningful endpoint following institution of a therapeutic intervention. In RA, clinical remission would therefore be graded as a DAS28 score of ≤2.6 with disease flare accompanying scores of ≥5.1; well-controlled disease is best characterized as fitting in between these two scores.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Low Disease Activity at Week 24
ParticipantsAdalimumab 40 mgNamilumab 150 mg
Number of Participants Who Achieved Low Disease Activity at Week 2424
SecondaryNumber of Participants Who Achieved ACR 20, 50, and 70 at Week 24

The American College of Rheumatology (ACR) 20 is composite index of improvement in RA proposed by the ACR. ACR20 refers to a composite improvement of 20% in swollen joint count, tender joint count, and 3 or more of the following 5 measures: Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity, Patient Pain VAS, Patient's self-addressed disability (HAQ), Acute-phase reactant (ESR or CRP) The ACR 50 and ACR 70 are similar tools, used to indicate 50% and 70% improvement, respectively.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Number of Participants Who Achieved ACR 20, 50, and 70 at Week 24
ParticipantsAdalimumab 40 mgNamilumab 150 mg
ACR 2024
ACR 5023
ACR 7012
SecondaryChange From Baseline in DAS28-CRP Score

The DAS28-CRP is a composite measure of inflammation in RA and incorporates a tender and swollen joint count, CRP and patient global assessment of disease activity expressed in a gaussian distribution of variables ranging from 0 to 10. A DAS28-CRP score of \<3.2 suggests a low level of disease activity, while a score of \>5.1 suggests a high level of disease activity. Using the DAS-CRP as a continuous scale allows investigators (and clinicians) to measure a clinically meaningful endpoint following institution of a therapeutic intervention. In RA, clinical remission would therefore be graded as a DAS28 score of ≤3.2 with disease flare accompanying scores of ≥5.1; well-controlled disease is best characterized as fitting in between these two scores.

Time frame:
Baseline Up to Week 42
Reported as:
Mean · score on a scale
Change From Baseline in DAS28-CRP Score
score on a scaleAdalimumab 40 mgNamilumab 150 mg
Week 2-0.55 ± 0.737-0.78 ± 0.333
Week 6-1.36 ± 1.086-1.58 ± 0.494
Week 10-1.74 ± 1.103-1.83 ± 0.344
Week 12-1.94 ± 1.036-2.12 ± 0.613
Week 18-2.05 ± 1.136-2.72 ± 0.486
Week 24-2.04 ± 1.596-2.99 ± 0.216
Week 32-1.89 ± 1.946-2.38 ± 0.862
Week 42-1.99 ± 1.938-1.57 ± 1.387

Adverse events

Collected over Baseline up to Week 42. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adalimumab 40 mg—0/3 (0%)3/3 (100%)
Namilumab 150 mg—1/4 (25%)4/4 (100%)
Most frequent serious events
Most frequent serious events
EventAdalimumab 40 mgNamilumab 150 mg
Cellulitis streptococcalInfections and infestations0/31/4
Most frequent other events
Showing 10 of 13
Most frequent other events
EventAdalimumab 40 mgNamilumab 150 mg
Urinary tract infectionInfections and infestations1/31/4
NeutropeniaBlood and lymphatic system disorders1/30/4
Forced vital capacity decreasedInvestigations1/30/4
Streptococcal sepsisInfections and infestations0/31/4
Joint swellingMusculoskeletal and connective tissue disorders0/31/4
PyrexiaGeneral disorders0/31/4
Alanine aminotransferase increasedInvestigations0/31/4
Aspartate aminotransferase increasedInvestigations0/31/4
Forced expiratory volume decreasedInvestigations0/31/4
Neutrophil count decreasedInvestigations0/31/4

Baseline characteristics

Full analysis set included participants who received at least one dose of study medication.

Age, Continuous
Age, Continuous(years)Adalimumab 40 mgNamilumab 150 mgTotal
Mean63.0 ± 7.2161.3 ± 6.9062.0 ± 6.48
Age, Customized
Age, Customized(Participants)Adalimumab 40 mgNamilumab 150 mgTotal
45 to 64 years134
>= 65 years213
Sex: Female, Male
Sex: Female, Male(Participants)Adalimumab 40 mgNamilumab 150 mgTotal
Female202
Male145
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Adalimumab 40 mgNamilumab 150 mgTotal
White347
Region of Enrollment
Region of Enrollment(Participants)Adalimumab 40 mgNamilumab 150 mgTotal
Estonia123
Russia224
Height
Height(cm)Adalimumab 40 mgNamilumab 150 mgTotal
Mean171.7 ± 8.96162.5 ± 3.00166.4 ± 7.44
Weight
Weight(kg)Adalimumab 40 mgNamilumab 150 mgTotal
Mean106.67 ± 16.19778.83 ± 16.55090.76 ± 21.116
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Adalimumab 40 mgNamilumab 150 mgTotal
Mean36.77 ± 8.80629.68 ± 5.84432.71 ± 7.569

1 further baseline measures are reported on the registry.

08

Study locations

13 sites
  • Pardubice, Czechia
  • Praha 3, Czechia
  • Tallinn, Estonia
  • Tartu, Estonia
  • Moscow, Russian Federation
  • Yaroslavl, Russian Federation
  • Santiago de Compostela, La Coruna, Spain
  • Fuenlabrada, Madrid, Spain
  • La Coruna, Spain
  • Madrid, Spain
  • London, Greater London, United Kingdom
  • Salford, Greater Manchester, United Kingdom
  • Oxford, Oxfordshire, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2015 to primary completion in Jun 2016, 14 months.

Results were first posted in Feb 2019, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2015
First posted
Mar 19, 2015
StartActual
Apr 8, 2015
Primary completionActual
Jun 27, 2016
CompletionActual
Nov 16, 2016
Results first posted
Feb 5, 2019
Last update
Feb 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02393378
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Mar 19, 2015
Start date
Apr 8, 2015
Primary completion
Jun 27, 2016
Completion
Nov 16, 2016
Results posted
Feb 5, 2019
Last update
Feb 5, 2019

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion